Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned an average rating of “Moderate Buy” from the twenty-one research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $159.45.

Several analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Guggenheim lowered their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Piper Sandler increased their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Royal Bank of Canada decreased their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bleakley Financial Group LLC bought a new stake in Illumina during the 4th quarter worth about $751,000. Zacks Investment Management bought a new stake in shares of Illumina during the third quarter valued at approximately $2,924,000. Van ECK Associates Corp increased its holdings in shares of Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after purchasing an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $1,464,000. Finally, Allworth Financial LP raised its position in Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after purchasing an additional 6,263 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of Illumina stock opened at $97.20 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a market cap of $15.40 billion, a PE ratio of -12.66, a price-to-earnings-growth ratio of 1.67 and a beta of 1.10. The firm has a fifty day moving average price of $128.97 and a two-hundred day moving average price of $134.16. Illumina has a fifty-two week low of $95.23 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts expect that Illumina will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.